Total
0
Shares
Neuren Pharmaceuticals (ASX:NEU) - Outgoing Executive Chairman, Dr Richard Treagus - The Market Herald
Outgoing Executive Chairman, Dr Richard Treagus
Source: The Australian
  • Therapy developer Neuren Pharmaceuticals (NEU) has started producing its treatment for an upcoming phase two trial
  • The treatment, officially known as NNZ-2951, is being tested against Phelan-McDermid syndrome, Angelman syndrome and Pitt Hopkins syndrome
  • These are neurological disorders, characterised by "impaired connections and signalling between brain cells" in humans
  • Neuren says the same manufacturer which produced the treatment for its phase one NNZ-2951 trial will also create this larger batch
  • The healthcare stock intends to begin the phase two study at some stage next year
  • Neuren shares ended the day in the grey, trading for $1.17

Therapy developer Neuren Pharmaceuticals (NEU) has started producing its treatment for an upcoming phase two trial.

The treatment, officially known as NNZ-2951, is being tested against Phelan-McDermid syndrome, Angelman syndrome and Pitt Hopkins syndrome. These are neurological disorders, characterised by "impaired connections and signalling between brain cells" in humans.

Neuren says the same manufacturer, which produced the treatment for its phase one NNZ-2951 trial, will create this larger batch.

"We have made excellent progress in the optimisation and scale-up of the manufacturing process for NNZ-2591," Neuren CEO Jon Pilcher commented.

"This investment is another important stepping-stone towards the phase two trials in 2021, in which we aim to confirm the potential of NNZ-2591 to address the urgent unmet need in three serious childhood disorders," he continued.

Neuren intends to begin its phase two NNZ-2591 study at some stage next year.

The pharmaceutical company, which is headquartered in Victoria, is currently developing two treatments to treat five neurological disorders.

These disorders, which often appear in early childhood, currently have no cure — meaning many of Neuren's treatments have been fast-tracked by the U.S. Food and Drug Administration (FDA) or been awarded orphan drug designation in the U.S. and the E.U.

The healthcare stock's flagship product, known as trofinetide, or NNZ-2566, is currently being tested as a treatment for Rett and Fragile X syndrome.

At this stage, the company is trialling trofinetide against Rett syndrome in a phase three study, while Neuren recently completed a phase two clinical trial, testing the drug against Fragile X syndrome.

Neuren shares ended the day in the grey, trading for $1.17 each at market close.


Subscribe


NEU by the numbers
More From The Market Herald
EVE Investment (ASX:EVE) - Managing Director, Bill Fry - The Market Herald

" EVE Investments (ASX:EVE) increases revenue and cash balance in Q1 FY21

Wellness business EVE Investments (EVE) has announced a record start to FY21, increasing both its revenue and cash balance during the September quarter.
Holista Colltech (ASX:HCT) - Managing Director, Dr Rajen Manicka - The Market Herald

" Holista CollTech’s (ASX:HCT) Path-Away kills 99.9pc of COVID-19

The coronavirus rollercoaster continues for small-cap biotech company Holista CollTech (HCT) today, with its share price almost doubling on the company’s latest announcement.
Imagion Biosystems (ASX:IBX) appoints Geoff Hollis as CFO

" Imagion Biosystems (ASX:IBX) appoints Geoff Hollis as CFO

Imagion Biosystems (IBX) has appointed Geoff Hollis as its new Chief Financial Officer (CFO).
Anteris Technologies (ASX:AVR) - CEO, Wayne Paterson - The Market Herald

" Anteris Technologies (ASX:AVR) one step closer to biologic heart valve

Anteris Technologies (AVR) is continuing to make progress in the development of its DurAVR 3D single-piece aortic valve.